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Abstract
Background: Compared to subgroup analyses in a single study or in a traditional meta-analysis, an individual
patient data meta-analysis (IPDMA) offers important potential advantages. We studied how many IPDMAs report on
surgical interventions, how many of those surgical IPDMAs perform subgroup analyses, and whether these
subgroup analyses have changed decision-making in clinical practice.
Methods: Surgical IPDMAs were identified using a comprehensive literature search. The last search was conducted
on 24 April 2012. For each IPDMA included, we obtained information using a standardized data extraction form,
and the quality of reporting was assessed. We also checked whether results were implemented in clinical
guidelines.
Results: Of all 583 identified IPDMAs, 22 (4%) reported on a surgical intervention. Eighteen (82%) of these IPDMAs
presented subgroup analyses. Subgroups were mainly based on patient and disease characteristics. The median
number of reported subgroup analyses was 3.5 (IQR 1.25-6.5). Statistical methods for subgroup analyses were
mentioned in 11 (61%) surgical IPDMAs.
Eleven (61%) of the 18 IPDMAs performing subgroup analyses reported a significant overall effect estimate, whereas
six (33%) reported a non-significant one. Of the IPDMAs that reported non-significant overall results, three IPDMAs
(50%) reported significant results in one or more subgroup analyses. Results remained significant in one or more
subgroups in eight of the IPDMAs (73%) that reported a significant overall result.
Eight (44%) of the 18 significant subgroups appeared to be implemented in clinical guidelines. The quality of
reporting among surgical IPDMAs varied from low to high quality.
Conclusion: Many of the surgical IPDMAs performed subgroup analyses, but overall treatment effects were more
often emphasized than subgroup effects. Although, most surgical IPDMAs included in the present study have only
recently been published, about half of the significant subgroups were already implemented in treatment guidelines.
Background
Surgery has advanced spectacularly in the past 50 years,
but many advances have not come from carefully
planned research using valid study designs [1]. Research
on surgical interventions is associated with several meth-
odological and practical challenges of which few, if any,
apply only to surgery. Surgical innovation is especially
demanding because many of these challenges coincide
[2]. Perhaps this situation leads many surgeons to view
randomized controlled trials (RCTs), although theoretic-
ally advantageous, to be too difficult and impractical to
undertake, and even worse, irrelevant to their practice
because of concerns about generalizability [2,3].
The results of RCTs are usually implemented in prac-
tice by either treating or testing all patients in case of a
‘positive’ study or treating or testing no-one in case of a
‘negative’ study. Clinicians intuitively know that this ap-
proach is oversimplified because in reality some patients
benefit more than average whereas others do not benefit.
This may explain why around 50% of the RCTs perform
subgroup analyses [4,5]. However, misleading claims
about subgroup effects based on a single study are com-
mon [6].
Investigating subgroups is a highly relevant, but com-
plex topic because of two interrelated concerns: failure
to detect a relevant subgroup effect (false negative), and
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a misleading claim about a subgroup effect which in
reality does not exist (false positive). Both of these prob-
lems can lead to suboptimal care for patients. Subgroup
effects have been extensively and fiercely debated in the
clinical, epidemiological, and statistical literature, espe-
cially in the context of single trials or traditional meta-
analyses based on published summary results [7-11].
Individual patient data meta-analyses (IPDMAs) differ
from traditional meta-analyses in that an IPD meta-
analysis uses the ‘raw data’ of individual patients from
included studies instead of the published summary re-
sults of studies in a traditional meta-analysis [12]. Com-
pared to subgroup analyses in a single study or in a
traditional meta-analysis, an IPDMA offers important
potential advantages, such as: (1) increased possibilities
to perform more complex statistical analyses that better
match the underlying data; (2) more power compared
to single studies and traditional meta-analyses; (3) higher
validity of subgroup analyses by avoiding ecological bias
and by taking the distribution of other patient charac-
teristics into account; (4) improved flexibility and stan-
dardization of defining subgroups across studies; and (5)
opportunities to examine the consistency of subgroup
effects across studies [13-17].
In this paper we present a systematic overview of
all IPDMAs on surgical interventions published. We
studied the number and types of subgroup analyses
performed, and whether these subgroups analyses
influenced decision-making in clinical practice.
Methods
Search
A comprehensive literature search in PubMed, Embase,
Web of Science, and the Cochrane Library was
conducted to identify all IPDMAs of RCTs. The last
search was conducted on 24 April 2012. Keywords used
to develop our search strategy were ‘individual patient
data’ and ‘meta-analysis’ (see Additional file 1 for de-
tailed search strategy).
Selection
In first instance, titles and abstracts were screened to
identify eligible IPDMAs. Selection of potential eligible
IPDMAs was restricted to IPD obtained from RCTs
comparing surgical interventions. Patients had to be ran-
domized over a surgical intervention in at least one
treatment arm, and the surgical procedures had to be
performed under general, spinal, epidural, or regional
anesthesia. IPDMAs regarding drug-eluting medical de-
vices and surgical trials in which a drug was the com-
parison were excluded.
Full text papers were retrieved when meta-analytic
techniques for individual patient data of RCTs were
used. IPDMAs using the same dataset or combination
of datasets, studying/addressing different questions/
subgroups were included. If obvious duplicate pa-
pers were available, the most elaborate paper was
included.
Data extraction and analysis
Data from all included surgical IPDMAs were extracted
with respect to specific characteristics, that is, publica-
tion year, number of included trials and patients, do-
main, type of intervention, comparison, and outcome
measured. Regarding the subgroups, number, type, justi-
fication, statistical methods, and results in relation to
the overall effect estimate were studied.
We classified five types of subgroups, patient charac-
teristics (for example, age or gender), disease character-
istics (for example, severity or co-morbidity), household
characteristics (for example, socioeconomic status or
smoking), intervention characteristics (for example, type
of intervention or dose), and methodological characteris-
tics (for example, quality of included trials or trial
effect). Justification for subgroups analyses was catego-
rized as based on literature, clinical experience, bio-
logical mechanism, or no justification.
We also assessed the quality of reporting of all selected
IPDMAs. IPDMAs on RCTs should be reported
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) [18]. Since
this guideline is not specific to IPDMAs, it has been sug-
gested that some additional information should be
reported, for instance why the IPDMA approach was ini-
tiated, whether there was a protocol for the IPDMA pro-
ject, and whether a one-step or a two-step analysis was
performed [12]. We judged the quality of reporting
based on the 18 criteria suggested by Riley et al. [12].
Two independent reviewers (GH and MMR) selected eli-
gible surgical IPDMAs and extracted data (duplicate in-
dependently). Any disagreements were resolved by
consensus.
Finally, we reviewed available clinical guidelines for
recommendations based on significant results of sub-
group analyses from IPDMAs to determine the extent to
which these results were implemented in clinical guide-
lines. We conducted a PubMed search for fields ‘pa-
tients’ (for example, carotid stenosis), ‘intervention’ (for
example, carotid stenting) and ‘comparison’ (for ex-
ample, endarterectomy), extracted from IPDMAs with
significant subgroup analyses, and limited our search to
‘Practice Guideline’. We only included publications in
English. We also searched the National Library of
Guidelines (http://guidance.nice.org.uk/), and the Na-
tional Guideline Clearinghouse (http://www.guidelines.
gov/).
All steps in this review were carried out according to a
pre-defined protocol (Additional file 2).
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Results
Search
In the search for IPDMAs, 3,597 potential eligible papers
were identified. After studying the abstracts, 583 papers,
published between 1991 and 2012, indeed reported an
IPDMA. After detailed evaluation, 22 (4%) IPDMAs
reported on a surgical intervention and met our inclu-
sion criteria (Figure 1; Additional file 3).
Of the 22 surgical IPDMAs, 12 focused on cardiovas-
cular interventions, three on inguinal hernia repair, three
on gynecological interventions, two on orthopedic inter-
ventions, one on a gastroenterological intervention, and
one on ventilation tubes for otitis media (Table 1). The
surgical IPDMA papers were published between 2005
and 2012. Eighteen (82%) of the 22 surgical IPDMAs
tried to identify subgroups of patients that benefit more
or less from the surgical intervention.
The remaining non-surgical IPDMAs predominantly
focused on cancer, cardiovascular disease, and diabetes,
and most assessed whether a treatment or intervention
was effective, often in subgroups of patients. Before 2000
only a few IPDMAs were published, whereas a consider-
able rise in the number of published IPDMAs is seen be-
tween 2005 and 2012 (Figure 2). This growth is most
likely the result of an increased awareness the potential
advantages of IPDMAs, and the initiation of collabora-
tions to specifically perform such studies.
Summary of IPDMAs using IPD (or part of IPD) from the
same trials
Of the 12 IPDMAs that focused on a cardiovascular
intervention, four IPDMAs [26-29] used individual pa-
tient data from the same 22 trials (6,763 patients) evalu-
ating the clinical effects of primary percutaneous coronary
Figure 1 Flowchart of study selection process for IPDMA of surgical interventions.
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Table 1 Characteristics of the 22 identified surgical IPDMAs
Author and year RCTs
(n)
Patients
(n)
Patients Intervention Comparison Outcome Subgroups (n) Overall
effect
estimate
Significant
effect
estimates
in
subgroups
(n/N)
Jorgenson et al., 2007
[19]
7 2,091 Women with
cervical
insufficiency
Cervical cerclage Expectant
management, no
cerclage
Primary Obstetric history, cervical length
(2)
NS 0/2
Pregnancy loss or neonatal death
before discharge from hospital
Secondary
Preterm delivery and maternal
morbidity
Hlatky et al., 2009 [20] 10 7,812 Patients with
multivessel
coronary disease
Coronary artery
bypass graft
Percutaneous
coronary
intervention
All-cause mortality Age, sex, diabetes, smoking,
hypertension,
hypercholesterolaemia, PVD,
stability of symptoms, previous
MI, heart failure, LV function, no.
of diseased vessel, proximal LAD,
balloon vs.stent (14)
NS 2/14
Daniels et al., 2010
[21]
5 862 Patients with
chronic pelvic
pain
Laparoscopic
uterosacral nerve
ablation (LUNA)
No LUNA Derived measure of worst pain
level experienced
Presence of visual pathology, site
of pain, age, parity (4)
NS 1/4
Burzotta et al., 2009
[22]
11 2,686 Patients with ST-
elevation
myocardial
infarction (STEMI)
Percutaneous
coronary
intervention with
thrombectomy
Standard
percutaneous
coronary
intervention
Primary Manual vs. non-manual
thrombectomy devices, diabetes,
primary vs. rescue PCI, treated vs.
non-treated with IIb/IIIa-inhibitors,
ischemic time, infarct-related
artery, pre-PCI TIMI flow (7)
S 1/7
All-cause mortality
Secondary
Survival free from MI, TLR, or TVR,
major adverse coronary events
(MACE), death+MI
Carotid Stenting
Trialists’Collaboration,
2010 [23]
3 3,433 Patients with
symptomatic
carotid stenosis
Carotid stenting Endarterectomy Primary Age, sex, diabetes, hypertension,
SBP, hypercholesterolaemia,
smoking, coronary heart disease,
peripheral artery disease, most
recent ipsilateral ischemic event,
history of stroke, degree of
ipsilateral ischemic stroke,
contralateral severe carotid
stenosis or occlusion, treatment
within 14 days, patients recruited
per center, center recruitment
rate (16)
S 1/16
Any stroke or death
Secondary
Disabling stroke or death, all-
cause death, any stroke,
myocardial infarction, severe local
hematoma, severe wound
infection
Middleton et al., 2010
[24]
17 2,814 Patients with
heavy menstrual
bleeding
Hysterectomy,
endometrial
destruction (1st &
2nd generation),
levonorgestrel
Endometrial
destruction (1st &
2nd generation),
levonorgestrel
releasing intra-
Dissatisfaction rates Uterine cavity length, age,
presence of fibroids/polyps,
parity, baseline bleeding score (5)
S 1/5
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Table 1 Characteristics of the 22 identified surgical IPDMAs (Continued)
releasing intra-
uterine system
(MIRENA)
uterine system
(MIRENA)
Mercado et al., 2005
[25]
4 3,051 Patients with
multi-system
coronary artery
disease
Percutaneous
coronary
intervention with
multiple stenting
Coronary artery
bypass graft
Primary Age, gender, diabetes, smoking,
number of diseased vessels (5)
NS 0/5
Composite of death, MI, or stroke
at 1 year FU
Secondary
Death, composite of death or MI,
repeat revascularization,
composite of death, MI, stroke,
and repeat revalscularization
Boersma et al., 2006
[26]
22 6,767 Patients with
acute myocardial
infarction
PCI Fibrinolysis All-cause mortality Age, sex, diabetes, prior MI, MI
location, heart rate, SBP,
fibrinolytic agent, front-loaded
tPA, site volume (11)
S 1/11
Timmer et al., 2007
[27]
19 6,315 Patients with
acute myocardial
infarction
PCI Fibrinolysis Death, recurrent MI, death or
recurrent MI, stroke
Diabetes (1) S 0/1
de Boer et al., 2010
[28]
22 6,767 Patients with
acute myocardial
infarction
Primary PCI Fibrinolysis Primary Age (1) S 0/1
All-cause mortality
Secondary reMI, stroke, composite
of all-cause mortality or reMI,
composite of all-cause mortality,
reMI, or stroke
de Boer et al., 2011
[29]
22 6,767 Patients with
acute myocardial
infarction
Primary PCI Fibrinolysis All-cause mortality High-risk patients (1) S 0/1
Fox et al., 2010 [30] 3 5,467 Patients with
non-ST-elevation
myocardial
infarction
Routine invasive
strategy
Selective invasive
strategy
Primary High-risk groups based on
baseline characteristics (1)
S 1/1
Composite of CV death or non-
fatal MI
Secondary
All-cause death, non-fatal MI
alone
Damman et al., 2012
[31]
3 5,467 Patients with
non-ST-elevation
myocardial
infarction
Routine invasive
strategy
Selective invasive
strategy
Primary Age (1) S 1/1
Composite of CV death or non-
fatal MI, CV death, MI
Damman et al., 2012
[32]
3 5,467 Patients with
non-ST-elevation
myocardial
infarction
Routine invasive
strategy
Selective invasive
strategy
All-cause mortality Procedure-related MI,
spontaneous MI (2)
S 1/2
Biau et al., 2009 [33] 6 423 Primary S 2/3
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Table 1 Characteristics of the 22 identified surgical IPDMAs (Continued)
Patients with
symptomatic
unilateral anterior
cruciate ligament
injury
Reconstruction with
patellar tendon
autograft
Reconstruction
with hamstring
tendon autograft
Gender, age at surgery, trial effect
(3)
Positive pivot-shift test Secondary
Positive Lachman test
Rovers et al., 2005
[34]
7 1,234 Children with
otitis media with
effusion
Short-term
ventilation tubes
Watchful waiting Mean time spent with effusion,
hearing, language development
Hearing level at baseline, history
of acute otitis media, upper
respiratory infections, attending
day care, socioeconomic status,
siblings, season, history of
breastfeeding, parental smoking
(9)
NS 2/9
Salerno et al., 2007
[35]
4 305 Cirrhotic patients
with refractory
ascites
Transjugular
intrahepatic
portosystemic shunt
(TIPS)
Paracentesis Primary NA S NA
Death from any cause before LT
Secondary
Liver-related death
Staples et al., 2011
[36]
2 209 Patients with
osteoporotic
vertebral
compression
fractures
Vertebroplasty Sham Scores for pain and function Onset of pain, pain scores at
baseline (2)
NS 0/2
McCormack et al.,
2003 [37]
25 4,165 Patients with
clinical diagnosis
of groin hernia
for whom
surgical
management was
judged
appropriate
Laparoscopic repair Open repair Duration of operation, ‘opposite’
method initiated, conversion,
hematoma, seroma, wound/
superficial infection, mesh/deep
infection, port site hernia, vascular
injury, visceral injury, length of
hospital stay, time to return to
usual activities, persisting pain,
persisting numbness, hernia
recurrence, known death within
30 days of surgery
NA S NA
(Transabdominal
preperitoneal repair
(TAPP) or totally
extraperitoneal
repair (TEP))
Scott et al., 2002 [38] 11 3,347 Patients with
clinical diagnosis
of groin hernia
for whom
surgical
management was
judged
appropriate
Mesh technique Non-mesh
technique
Duration of operation, ’opposite’
method initiated, conversion,
hematoma, seroma, wound/
superficial infection, serious
complications, length of
postoperative hospital stay, time
to return to usual activities,
persisting pain, persisting
numbness, hernia recurrence,
known death
NA S NA
EU Hernia Trialists
Collaboration, 2002
[39]
35 6,901 Patients with
clinical diagnosis
of groin hernia
for whom
surgical
Laparoscopic repair,
mesh methods
Open repair, non-
mesh methods
Hernia recurrence, persisting pain NA S NA
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Table 1 Characteristics of the 22 identified surgical IPDMAs (Continued)
management was
judged
appropriate
Gregson et al., 2012
[40]
8 2,186 Patients with
spontaneous
supratentorial
intracerebral
hemorrhage
Surgery Conservative
treatment
Unfavorable outcome Location of hematoma, time from
event, age, Glascow Coma Score,
volume of hematoma (5)
NA 4/5
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intervention versus in-hospital fibrinolysis. In three IPDMAs
[30-32], comparing routine invasive strategies with se-
lective invasive strategies in 5,467 patients with non-
ST segment elevation acute coronary syndromes, data
from the same three trials (FRISC II, ICTUS, and
RITA-3) were used. In addition, of the three IPDMAs
that focused on inguinal hernia repair one IPDMA
[39] presented a combination of the data used in the
other two IPDMAs [37,38].
Number, justification, type, and methods of subgroups
analyses in surgical IPDMAs
In 18 (82%) of the full set of surgical IPDMAs assessed,
subgroup analyses were performed to examine whether
certain patients benefit more from a specific treatment
than others. The median number of subgroups reported
in these IPDMAs was 3.5 (range, 1–16, IQR 5.25 (1.25-
6.5)). In 12 (67%) of the 18 surgical IPDMAs that stud-
ied subgroups a justification for subgroup analyses was
mentioned. Scientific literature was used for justification
in these studies.
The types of subgroups studied varied. Fifteen (83%)
IPDMAs studied patient characteristics, five (28%) stud-
ied household characteristics, 15 (83%) studied disea-
se characteristics, and six (33%) studied intervention-
related subgroups. Subgroups related to study or trial
effects were studied in three (17%) IPDMAs. No IPDMAs
studied subgroups related to the quality of the included
trials, for example concealment of allocation, blinding, or
completeness of follow-up.
Twelve (55%) IPDMAs stratified their analysis per trial
before pooling the results (two-step analysis). A one-step
analysis was performed in four (18%) IPDMAs. Statistical
methods for subgroup analyses were mentioned in 11
(61%) of the 18 IPDMAs performing subgroup analyses.
All IPDMAs that mentioned statistical methods for sub-
group analysis used interaction tests.
Only five (28%) surgical IPDMAs mentioned the power
of the subgroup analyses. Three IPDMAs reported that
their studies were underpowered to detect subgroup ef-
fects, one IPDMA reported that their study was well
powered to detect subgroups effects, however, did fail to
show differences in subgroups, and one IPDMA men-
tioned differences in power between different subgroups,
but not whether these were over- or underpowered.
Eleven (61%) of the 18 IPDMAs performing subgroup
analyses reported a significant overall effect estimate,
whereas six (33%) reported a non-significant one. One
IPDMA (6%) did not report an overall effect estimate
and only presented results of subgroup analyses [40].
Of the IPDMAs that reported non-significant overall
results, three IPDMAs (50%) reported significant results
in one or more subgroup analyses. Results remained sig-
nificant in one or more subgroups in eight of the
IPDMAs (73%) that reported a significant overall result.
Thirty-six (40%) of the total number of 90 subgroups ana-
lyses were performed on a non-significant or inconclusive
overall effect estimate, whereas 49 (54%) were performed on
a significant overall effect estimate. The remaining five (6%)
subgroups originated from the one IPDMA that did not re-
port an overall effect estimate and only presented results of
subgroup analyses, four out of these five subgroups being sig-
nificant [40]. Of the subgroup analyses performed on non-
significant overall results, five (14%) became significant. Nine
(18%) of those performed on IPDMAs with a significant
overall result remained significant.
Figure 2 Number of applied IPDMA published up to April 2012,* as identified by a systematic review of PubMed, Embase, Web of
Science, and the Cochrane Library. *Thirty-seven IPDMAs published in 2012 were identified up to 24 April 2012, when the review
was conducted.
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Eight (67%) of the 12 surgical IPDMAs with significant
subgroups reported on what the implications of these
significant results of their subgroup analyses were for
clinical practice. Mainly, the importance of differentiat-
ing when evaluating the efficacy and safety of new med-
ical and interventional treatments, and translating these
findings in treatment recommendations were empha-
sized. Moreover, it was reported that the influence of
certain subgroups had not been reported previously, that
findings concurred with recent recommendations or
guidelines, and that subgroups not per se needed to be
an exclusion criterion for treatment. Eight (44%) of the
18 significant subgroups were implemented in clinical
guidelines.
Quality of reporting
The quality of reporting of the surgical IPDMAs varied
(Figure 3). More than half of the IPDMA failed to report
whether or not there was a protocol for the IPDMA pro-
ject available. The reason why the IPD approach was ini-
tiated and the numbers of patients within each of the
original studies were generally well reported. For 17
(77%) IPDMAs, the process used to identify relevant
studies for the IPDMA were reported. Details on the
statistical analysis were reported in 16 (73%) IPDMAs,
however, details on the identification process and statis-
tical analysis were not described in one IPDMA (4%),
and were unclear in the remaining five (23%) IPDMAs.
Discussion
Our systematic review of all IPDMAs on surgical inter-
ventions published so far provides an overview of the
potential advantages of IPDMAs (see Table 2 for exam-
ples). In 18 (82%) of the full set of 22 surgical IPDMAs
assessed, subgroup analyses were performed to examine
whether certain patients benefit more from a specific
treatment than others. Eight (67%) of the 12 surgical
IPDMAs with significant subgroups reported on what
the implications of their findings were for clinical prac-
tice. Forty-four percent (8 out of 18) of the significant
subgroups were implemented in clinical guidelines.
Although many IPDMAs performed subgroup ana-
lyses, the overall treatment was usually the main focus
of the paper. Only occasionally subgroup analyses were
emphasized. In surgical IPDMAs, similar to IPDMAs in
general [42], subgroups were often based on patient and
disease characteristics. The median number of sub-
groups has been reported to range from 2 to 4, the max-
imum number of subgroups from 15 to 50 [6,43-45],
which is comparable to our findings. Justification of sub-
group analyses, the methods used to perform subgroup
analyses, and power calculations for performing sub-
group analyses are often not reported in IPDMAs
[6,43-48]. However, 11 (65%) of the IPDMAs included in
our study justified at least one of the subgroups on
which they reported, scientific literature being the mode
of justification used. This is in line with other studies
that found that clinical experience or biochemical justifi-
cation is rare [44,46,49]. Others showed that the propor-
tion of studies that used interaction tests for at least one
of their subgroups ranges from 10% to 56% [6,43-48],
which is slightly lower compared to our findings. So far,
few studies mentioned the importance of the power of
subgroup analyses [6,44,50,51], and reported that many
Figure 3 Quality of IPDMA reporting surgical interventions. Numbers inside bars are numbers of studies.
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reports put too much emphasis on subgroup analyses
that commonly lacked statistical power. This is in agree-
ment with the results of the present study.
To the best of our knowledge we are the first to study
surgical IPDMAs, and illustrate the merits of this
method within surgery. However, some potential limita-
tions should also be discussed. First, our literature
search for surgical IPDMAs was limited to IPDMAs
with IPD obtained from RCTs comparing surgical inter-
ventions, excluding IPDMAs regarding drug-eluting
medical devices and surgical trials in which a drug was
the comparison, and records were limited to the English
language. We, however, believe that our review provides
a good representation of the method within the surgical
field. Second, reporting bias could not be entirely ex-
cluded, since reporting of subgroup effects in scientific
publications might be influenced by reviewers’ and edi-
tors’ opinions. Third, as most studies mentioned mul-
tiple subgroups, a clustering effect might occur for
reporting on justification and statistical methods. There-
fore, the results were reported on study level instead
of individual subgroup level. Fourth, in the 12 IPDMAs
of cardiovascular interventions reporting subgroup analyses,
several studies included a same set of trials and the pat-
tern of exploring heterogeneity among these studies
might be similar, that is, there might be a clustering ef-
fect. As this might impact the subsequent analyses as
well as the conclusion, we performed a sensitivity ana-
lysis. The outcomes and conclusions were not substan-
tially influenced by the inclusion of studies using the
same set of trials. Fifth, the time from publication to im-
plementation of a result into a guideline or clinical prac-
tice can be highly variable, and sometimes takes even
more than 10 years [52]. Most surgical IPDMAs in-
cluded in the present study have only recently been
published, and time to possible implementation has
been rather short. Therefore, we might have under-
estimated the implementation of results from IPDMAs
into guidelines and/or clinical practice.
Conclusions
One of the challenges in medicine is to rationally imple-
ment available therapies in clinical practice, in the ap-
propriate patients at the appropriate time. Findings from
IPDMAs might provide insight into opportunities to im-
prove evidence-based treatment decisions for patients.
Table 2 Two examples of differences in conclusions with regard to how patient-level characteristics modify treatment
effect
Example Description
Effectiveness of coronary artery bypass grafting vs. percutaneous
coronary interventions for multivessel disease.
A two-step meta-analysis of individual patient data from 7,812 patients included
in 10 randomized trials comparing coronary artery bypass grafting (CABG) and
percutaneous coronary intervention (PCI) in patients with multivessel coronary
artery disease, showed a similar overall treatment effect on long-term mortality
after CABG and PCI [20]. However, in diabetic patients mortality was substantially
lower in the CABG group than in the PCI group (HR 0.70, 95% CI 0.56-0.87).
Mortality was similar between groups in patients without diabetes (HR 0.98, 95%
CI 0.86-1.12; P=0.01 for interaction). Patient age modified the effect of treatment
on mortality with hazard ratios of 1.25 (95% CI 0.94-1.66) in patients aged <55
years, 0.90 (95% CI 0.75-1.09) in patients aged 55–64 years, and 0.82 (95% CI 0.70-
0.97) in patients aged ≥65 years (P=0.002 for interaction). Treatment effect was
not modified by other subgroups. CABG might be a better option for patients
aged ≥65 years and patients with diabetes since mortality was found to be
lower in these subgroups. These results have been implemented in clinical
guidelines [41].
Effectiveness of routine vs. selective invasive strategy in patients
with non-ST-segment elevation acute coronary syndrome.
An individual patient data meta-analysis of three randomized trials of routine
versus selective invasive strategies in patients with non-ST-segment elevation
acute coronary syndrome showed that a routine invasive strategy resulted in
significantly less cardiovascular deaths (CV deaths) or non-fatal myocardial
infarctions (MIs) compared to selective invasive strategies [30]. The authors used
patient’s baseline characteristics to develop a multivariable risk prediction model.
A simplified integer risk score was derived from the risk prediction model to
predict a patient’s 5-year probability of CV death or MI, and the patients were
categorized into three risk groups (low, intermediate, and high risk).
The treatment effect was similar between groups in patients with low-risk (HR
0.80 (95% CI 0.63-1.02)) and intermediate-risk (HR 0.81 (95% CI 0.66-1.01)) scores.
In patients with high-risk scores treatment favored routine over selective invasive
strategies (HR 0.68 (95% CI 0.53-0.86)). There were 2.0% (95% CI −4.1-0.1%) and
3.8% (95% CI −7.4- -0.1%) absolute risk reductions in CV death or MI in the low-
and intermediate-risk groups and an 11.1% (95% CI −18.4- -3.8%) absolute risk
reduction in the highest-risk patients. The multivariable risk prediction model has
not yet been implemented in clinical guidelines.
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IPDMA is an extremely powerful tool if used correctly
and provides the most definitive synthesis of the avail-
able evidence, also for potential subgroups. Despite the
recommendations available on reporting clinical trials
and meta-analyses, such as PRISMA [18], these guide-
lines have not been specifically developed for IPDMAs.
The development of a generally accepted guideline for
reporting on IPDMAs including subgroup analyses
should therefore be encouraged. This seems the only op-
tion to really improve the reporting, analyses, and claims
and applicability of subgroup effects in clinical research.
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